Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials - Wikidata - awgldk - TriplyDB

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

http://www.wikidata.org/entity/Q28730438

about

Melanoma: oncogenic drivers and the immune system Beyond BRAF: where next for melanoma therapy?Clinical advances in molecular biomarkers for cancer diagnosis and therapy BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal Genomics A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations.VarWalker: personalized mutation network analysis of putative cancer genes from next-generation sequencing data Guiding Oncology Patients Through the Maze of Precision Medicine.In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials.A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.BRAFV600E-mutant melanoma presenting with cardiac involvement.The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach.MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603.[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma.Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.MGDB: a comprehensive database of genes involved in melanoma.ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma Genetics of melanoma Thymic neoplasm: a rare disease with a complex clinical presentation Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.Building a personalized medicine infrastructure at a major cancer center.Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment.

P2860

Q26775598-10210097-C62E-4406-963D-0C915A0DFFAD Q27006853-069347B4-5DF7-4511-8234-5B6972CD5473 Q27027560-FBF02263-87B7-489C-8E95-C77D671D67CA Q27851843-C6AB3246-B34D-437F-9E5C-B58F15D385D7 Q27852730-622171D4-D678-486A-BD5D-BCCBA11B7D1D Q28542977-AB5938E5-9CA4-431D-853C-4E3FAD506B13 Q30360645-41BF3FC7-C505-4240-8649-E7D8BDBBD9C8 Q30754874-B1E5F47A-0536-409F-94CA-E8C6E175873F Q30773132-8D5D92C6-974F-43D7-8434-637F06B38E55 Q30936571-239C5D35-CFEE-4530-8A47-42900E6BEB67 Q33560928-E07D523D-B0D2-4B07-AD08-4A5391382BF5 Q33699641-5897F475-E3E8-467D-8067-6131C1E748F3 Q33716499-027EF172-3F8D-4E49-B190-7A406356C5D9 Q33749057-1E34B580-E8E5-42AF-94E5-9E1B4D893483 Q33762080-D9A8B558-33AB-42EB-8589-B4E6C18F9D6C Q33875566-1776DC25-D5E4-4A08-85D5-0CE455A817C9 Q34033475-C7515A91-B4DA-49B3-868B-6CE04E6085E6 Q34276579-684655A6-F17A-439F-AC02-0655DC4E0278 Q34316552-B960E85F-CD7A-479F-9BF0-3AFE7207EA86 Q34484174-EDF7ED59-558F-445F-8EC6-A54838DF7B6E Q34737289-76680C5D-17C1-42D8-842C-13C5DDA884CB Q34928118-9FBFAC6D-C7EC-4BE8-AE3B-9EC8A56CCB4F Q35154039-79171735-3B02-42D5-9326-AEE4F707F45D Q35273776-10AC9A2B-8EB4-49A0-A35A-FD7E4B1C72F0 Q35687295-0818FF28-91AD-431F-B38A-CB3A0113D369 Q35855226-A103C5BB-E6CB-4F80-859C-374A5187EA01 Q35932262-20C923D6-908E-4B36-A3FD-7BB775E48099 Q35998474-F4214457-E683-4FC5-8D15-9FF8ED2766FA Q35998823-45206837-EB4C-46FA-BC40-AD098F256F88 Q36064844-DD51052B-3C54-4E84-9E8E-65B373C29815 Q36109610-26351283-0289-4BC7-B1E4-25620E6D5981 Q36355962-70FE6665-34AD-4873-B506-A615B70D0594 Q36561655-3551EDC4-0C46-454C-B6B2-ED60A3881E86 Q36563659-727F0D02-4302-46B4-AC56-7D78D27D44CF Q36753888-AF459D73-D537-4FC1-9F4B-F59923FC36C1 Q36896131-FAF02C73-3882-41C0-B832-A3FCCB6919E9 Q36920304-336D6B97-3B01-44AA-BC04-599256D0CD0A Q36929987-DE1756B9-A63C-40DD-96EB-651E8A1D5827 Q36960097-BAF7DA4D-EC73-4D8C-8DD5-8965C1492D7B Q37051421-149224D3-124F-438A-A5B7-158093C867E4

P2860

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

http://www.wikidata.org/entity/Q28730438

description

2012 թուականին հրատարակուած գիտական յօդուած

@hyw

2012 թվականին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 2012

@ast

im Januar 2012 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: 2012)

@en

vedecký článok (publikovaný 2012)

@sk

vědecký článek publikovaný v roce 2012

@cs

wetenschappelijk artikel (gepubliceerd in 2012)

@nl

наукова стаття, опублікована у 2012

@uk

مقالة علمية (نشرت عام 2012)

@ar

name

Routine multiplex mutational p ...... type-driven therapeutic trials

@ast

Routine multiplex mutational p ...... type-driven therapeutic trials

@en

Routine multiplex mutational p ...... type-driven therapeutic trials

@nl

type

label

Routine multiplex mutational p ...... type-driven therapeutic trials

@ast

Routine multiplex mutational p ...... type-driven therapeutic trials

@en

Routine multiplex mutational p ...... type-driven therapeutic trials

@nl

prefLabel

Routine multiplex mutational p ...... type-driven therapeutic trials

@ast

Routine multiplex mutational p ...... type-driven therapeutic trials

@en

Routine multiplex mutational p ...... type-driven therapeutic trials

@nl

P1433

Q28730438-0550E718-EFD4-4326-AE5F-907226F31409

P1476

Q28730438-791B8ABC-2544-4531-81A2-77D11FBFB6A0

P2093

Q28730438-0179F2F2-7670-4FF9-95C7-E5B942B14BF2

Q28730438-0772DCA3-C39A-4D5D-9BF3-AF527F715425

Q28730438-26122ACD-5CF5-4998-9E40-5826853F213C

Q28730438-2C5F70F8-4579-4775-924B-E6F1BF87CC1A

Q28730438-3D273B72-71B2-4577-915E-B0A7B20B159B

Q28730438-509B3320-9B95-418C-BE8E-D487BE7E83D4

Q28730438-71160B99-740C-4D5D-A3C4-5F513C729FFA

Q28730438-79EDC49F-7BD2-491A-870F-AD0F3C213609

Q28730438-873353F7-45B8-459D-8541-CDB60F190BA2

Q28730438-8BC5B2CD-987A-4BF2-A878-30076E8944C3

P2860

Q28730438-000FDECD-283C-4158-9CE4-A0F639156642

Q28730438-065582EB-49CF-4765-A567-D240A93DB234

Q28730438-077BE00B-827B-4F16-9004-53005E72E2F8

Q28730438-08FDA14E-195C-445C-8A0C-027B431B58FA

Q28730438-1A1D2EF6-C032-48ED-81B1-7FA3F90B4EBA

Q28730438-238B8168-07C9-4BF0-9AFE-F7B7C32D43FC

Q28730438-26997AE8-A754-4A0D-BA0E-942BB64061C9

Q28730438-2A843616-65FB-4E46-962F-5385EB35C55D

Q28730438-2E39C101-7ED5-43CD-9B7C-92D0F5FADFC1

Q28730438-2EF8F51A-8EDC-40BF-B33A-21BBE4F7910D

P304

Q28730438-B4BCBF28-E54D-4CC8-9B33-41229ACCD73E

P31

Q28730438-868AC7D9-CE16-4642-BF70-87FDDE37E2D2

P3181

Q28730438-68D2B58C-8F0E-4486-BEDB-F155F4A94ACE

P356

Q28730438-3D867487-30E6-45E6-A5B2-92DBCF1DB2F4

P407

Q28730438-1017E84D-9BF5-4063-A875-933D71DFC8B6

P433

Q28730438-1ACA626F-CCD1-4C40-A7E7-E0CF3D67B652

P478

Q28730438-33AAA7C0-B5EB-4F11-BE68-43F37130EC54

P50

Q28730438-6BF0E358-9E4E-4A8A-B1E9-1620993A4F56

Q28730438-991241A4-483F-46E0-8EC4-551DFE122AFC

P577

Q28730438-C29554A0-BB58-418D-92EB-1BF55CE11EE5

P5875

Q28730438-6D06ED76-FF58-49FF-8C38-6BF9006CF26A

P698

Q28730438-A0B15E3B-E57C-4C8F-A565-9D144AB142BD

P932

Q28730438-C2389936-83C5-4C6B-A46F-2D5498C1FEAE

P3181

P356

JOURNAL.PONE.0035309

P1433

P1476

Routine multiplex mutational p ...... type-driven therapeutic trials

@en

P2093

A John Iafrate

http://www.w3.org/2001/XMLSchema#string

Ann Richmond

http://www.w3.org/2001/XMLSchema#string

Charles Terry

http://www.w3.org/2001/XMLSchema#string

Cindy L Vnencak-Jones

http://www.w3.org/2001/XMLSchema#string

Donald Hucks

http://www.w3.org/2001/XMLSchema#string

Donna J Hicks

http://www.w3.org/2001/XMLSchema#string

Dora Dias-Santagata

http://www.w3.org/2001/XMLSchema#string

Elizabeth Berry

http://www.w3.org/2001/XMLSchema#string

Jeffrey Sosman

http://www.w3.org/2001/XMLSchema#string

Kimberly Brown Dahlman

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Mutations in GNA11 in uveal melanoma

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

P304

e35309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1076671

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0035309

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Christine M. Lovly

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224847815

http://www.w3.org/2001/XMLSchema#string

P698

22536370

http://www.w3.org/2001/XMLSchema#string

P932

3335021

http://www.w3.org/2001/XMLSchema#string